Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4592547 | 0.86 | PKM (0.42) | TSHRALDH1A1PKMPOLBRYR2 | |
| SCHEMBL4592228 | 0.83 | PKM (0.40) | ALDH1A1PKMLMNAPOLBABCB1 | |
| SCHEMBL4591708 | 0.81 | PKM (0.53) | TSHRALDH1A1PKMSMN1; SMN2LMNA | |
| SCHEMBL5161855 | 0.80 | PKM (0.38) | TSHRALDH1A1PKMLMNARYR2 | |
| SCHEMBL4592565 | 0.78 | MTNR1A (0.43) | ABCB1ABCC1ABCG2 | |
| Hydrochloric Acid SCHEMBL4875908 | 0.77 | MTNR1A (0.42) | MAPTALDH1A1LMNAABCB1ABCC1 | |
| SCHEMBL4592013 | 0.75 | CREBBP (0.45) | MAPTALDH1A1PKMABCB1ABCC1 | |
| Hydrochloric Acid SCHEMBL4611337 | 0.74 | ABCB1 (0.37) | MAPTALDH1A1PKMPOLBABCB1 | |
| SCHEMBL4592515 | 0.73 | CSNK1E (0.47) | MAPTABCB1ABCC1 | |
| SCHEMBL4592770 | 0.70 | HTR2A (0.45) | MAPTALDH1A1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080226718-A1 | Indole and Azaindole Derivatives For the Treatment of Inflammatory and Autoimmune Diseases | BRANE DISCOVERY S.R.L (IT) | 2008-09-18 | — | — | US | claimed |
| EP-1945305-A2 | INDOLE AND AZAINDOLE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRANE DISCOVERY S.R.L. (IT) | 2008-07-23 | — | — | EP | claimed |
| US-20070248672-A1 | Indole and Azaindole Derivatives with Antitumor Action | NIKEM RESEARCH S.R.L. (IT) | 2007-10-25 | — | — | US | claimed |
| WO-2007048847-A2 | INDOLE AND AZAINDOLE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | NIKEM RESEARCH S.R.L. (IT) | 2007-05-03 | — | — | WO | claimed |
| EP-1750687-A2 | INDOLE AND AZAINDOLE DERIVATIVES WITH ANTITUMOR ACTION | NIKEM RESEARCH S.R.L. (IT) | 2007-02-14 | — | — | EP | claimed |
| WO-2005105213-A2 | INDOLE AND AZAINDOLE DERIVATIVES WITH ANTITUMOR ACTION | NIKEM RESEARCH S.R.L. (IT) | 2005-11-10 | — | — | WO | claimed |
| US-20080226718-A1 | Indole and Azaindole Derivatives For the Treatment of Inflammatory and Autoimmune Diseases | BRANE DISCOVERY S.R.L (IT) | 2008-09-18 | — | — | US | disclosed |
| EP-1945305-A2 | INDOLE AND AZAINDOLE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRANE DISCOVERY S.R.L. (IT) | 2008-07-23 | — | — | EP | disclosed |
| US-20070248672-A1 | Indole and Azaindole Derivatives with Antitumor Action | NIKEM RESEARCH S.R.L. (IT) | 2007-10-25 | — | — | US | disclosed |
| WO-2007048847-A2 | INDOLE AND AZAINDOLE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | NIKEM RESEARCH S.R.L. (IT) | 2007-05-03 | — | — | WO | disclosed |
| EP-1750687-A2 | INDOLE AND AZAINDOLE DERIVATIVES WITH ANTITUMOR ACTION | NIKEM RESEARCH S.R.L. (IT) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005105213-A2 | INDOLE AND AZAINDOLE DERIVATIVES WITH ANTITUMOR ACTION | NIKEM RESEARCH S.R.L. (IT) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070248672-A1 | Indole and Azaindole Derivatives with Antitumor Action | IDO1, IDO2, INMT | MAPT 4170/4885TSHR 1955/4885ALDH1A1 788/4885 |
| US-20080226718-A1 | Indole and Azaindole Derivatives For the Treatment of Inflammatory and Autoimmune Diseases | IDO1, IDO2, INMT | MAPT 4048/4885TSHR 368/4885ALDH1A1 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.